어두운 정장에 줄무늬 넥타이를 맨 중년 남성이 시카고 최고의 변호사들의 전문성을 반영하듯 흐릿한 기업 법률 사무실을 배경으로 전문적인 헤드샷을 찍기 위해 포즈를 취하고 있습니다.

제임스 W. 매튜스

파트너

제임스 W. 매튜스

파트너

James Matthews handles complex business disputes for a variety of businesses, including manufacturers of pharmaceutical products and medical devices, frequently representing life sciences and technology companies in commercial disputes pending in courts and before arbitrators throughout the country. In addition to representing these businesses in litigation, he is a trusted advisor to them in connection with the litigation risks associated with their businesses.

In the past 20 years, James has acted as lead counsel to generic drug manufacturers and pharmaceutical distributors in some of the most complex and multifaceted litigations pending in courts across the United States. He has also represented these companies as both defendant and plaintiff in commercial disputes, resulting in defense verdicts and plaintiffs’ verdicts and settlements collectively in excess of hundreds of millions of dollars.

Prior to joining Foley, James was a partner at another firm. He also was appointed Special Assistant District Attorney for Middlesex County for an interim period. For two years after law school, he clerked for The Honorable John E. Conway, U.S. District Judge for the District of New Mexico.

James is a member of the Commercial Litigation Practice Group and co-chair of the Pharmaceutical and Other Regulated Drugs Area of Focus within the firm’s Health Care & Life Sciences Sector.

For more than twenty years, James Matthews has tried complex, high-profile cases on behalf of clients in difficult circumstances. He has appeared in state and federal courts around the country, tried cases before judges and juries for plaintiffs and defendants, and won verdicts on behalf of both.  He past trials have included claims under the False Claims Act, federal and state antitrust statutes, and a variety of state unfair competition acts, as well as claims for fraud and breach of contract. In 2009, he obtained the “biggest verdict of the year” in Massachusetts in a patent infringement case. Six months later he “won” a mistrial when an Alabama jury was unable to agree that the pharmaceutical manufacturer he represented (Watson Pharmaceuticals) had defrauded the state of Alabama by submitting fake “Average Wholesale Prices” to Alabama Medicaid. Two years later, James won a unanimous defense verdict in another “AWP” case when a Kentucky jury rejected Kentucky’s identical claims against Watson. In 2015, he took a “pay-for-delay” antitrust cases to trial, representing generic pharma manufacturer Apotex Corp. against industry behemoths Cephalon, Teva, Mylan and Dr. Reddy’s and obtaining — after his closing argument — nine figures in settlements. In 2022 and 2023, James defended Anda, Inc. in two trials accusing it of fomenting and benefitting from the country’s “opioid crisis.” James honed his trial skills as a Special Assistant District Attorney in the Cambridge (Massachusetts) District Court, where he learned that attention to detail was second only to developing strong themes and delivering a clarifying narrative in the toolbox of successful trial lawyers.

대표 경험

  • Lead national counsel for an international generic drug manufacturer in the generic drug antitrust cases coordinated in the Eastern District of Pennsylvania. Responsible for coordinating claims under federal and state antitrust laws brought by the Attorneys General of most states and purchasers and payors of generic drugs, including Medicaid agencies, wholesalers and distributors, pharmacies, insurers, and consumers.
  • Lead national counsel to several drug manufacturers and a distributor of pharmaceutical products in hundreds of cases pending throughout the United States alleging the creation of a public nuisance arising from the sale and distribution of opioid products. Lead trial counsel for Anda, Inc. in New York state court jury trial and San Francisco federal court bench trial. Coverage of this engagement can be found at: https://www.law360.com/articles/1410255/-overheated-hyperbole-opioid-atty-gets-fiery-in-sf-trial
  • Lead national counsel for a NYSE-listed generic drug manufacturer and its affiliates in government enforcement actions pending in state and federal courts throughout the country. Responsible for coordinating the defense of civil actions under the Federal False Claims Act and analogous state statutes pending in federal court and in state courts in Alabama, Alaska, Idaho, Florida, Hawaii, Illinois, Kansas, Kentucky, Louisiana, Massachusetts, Mississippi, Missouri, New York, Oklahoma, South Carolina, Texas, Utah, and Wisconsin.
  • Lead counsel for international generic drug manufacturer in prosecution “pay-for-delay” antitrust action against brand manufacturer and several generic manufacturers, recovering settlements collectively in excess of US $150m on eve of submitting claims to jury following multi-week trial.
  • Lead counsel for international generic drug manufacturer in successful arbitration of complex commercial dispute that injured manufacturer’s reputation in significant government funded health care market.
  • Obtained a US $15.7m patent infringement verdict for NYSE-listed medical device manufacturer, following a seven-day jury trial and two days of deliberations. (This verdict is listed as #1 by Massachusetts Lawyers Weekly in “Top Verdicts of 2009.”)
  • Obtained summary judgment for publicly traded generic drug manufacturer in a claim for breach of contract and unfair trade practices where plaintiffs sought recovery of actual damages equal to US $60m; successfully defended appeal.
  • Represented a NYSE-listed medical device manufacturer in three-week arbitration, obtained US $30m award on behalf of client.
  • Represented a generic drug manufacturer in antitrust action resulting from defendants’ attempted enforcement of invalid and unenforceable patent; obtained settlement resulting in client reporting US $100m gain in publicly filed financial statements.
  • Represented venture capital firm in successful defense of efforts to obtain control of company from entrenched founders/managers.
  • Obtained substantial judgment for internet search engine in multi-day arbitration claiming right to purchase-price adjustment in connection with corporate acquisition.
  • Represented developer in breach of contract and unfair trade practices action, obtained order dismissing counterclaims, and obtained multi-million dollar settlement for client on first day of scheduled trial.

수상 및 표창

  • The Best Lawyers in America® in the field of Commercial Litigation (2023)
  • 동료 평가 등급: AV® Preeminent™, 마틴데일-허벨 동료 평가 등급 체계에서 최고 성능 등급
  • The Legal 500 for Health Care – Life Sciences
  • Massachusetts Super Lawyers® (2006, 2008-2013)

제휴

  • Member of the Massachusetts Bar Association
  • Member of the American and Boston Bar Associations’ Health Care Law, Litigation, and Business Law Sections
  • Member of the Defense Research Institute and its Drug and Medical Devices, Medical and Health Care Law, Construction Law, and ADR Sections
  • Elected to membership in the International Association of Defense Counsel, an invitation-only membership comprised of the world’s leading corporate and insurance lawyers and insurance executives

프레젠테이션 및 출판물

  • James is a frequent speaker on topics covering enterprise risk management; litigation prevention, assessment, and management; arbitration of complex business disputes; and depositions.
2025년 10월 30일 이벤트

주목해야 할 주요 제약 소송 동향

의료 및 생명과학 산업이 계속 진화함에 따라 전국의 조직은 제약 소송의 최근 동향을 염두에 두어야 합니다. 이 웨비나에서는 독점 금지, 지적 재산권, 대량 불법 행위 소송 또는 기타 소송 문제 등 제약 업계에서 증가하고 있는 제약 트렌드를 자세히 살펴봅니다.
Marble statue and columns at the entrance of the United States Supreme Court building, with "Equal Justice Under Law" inscribed above—a symbol recognized by lawyers in Chicago and beyond for upholding intellectual property law.
April 18, 2025 Foley Viewpoints

Supreme Court Ends Circuit Split with Ruling That Plaintiffs Can Seek RICO Damages for Certain Personal Injury Claims

The U.S. Supreme Court has broadened plaintiffs’ ability to sue under the Racketeer Influenced and Corrupt Organizations Act (RICO) for economic loss stemming from personal injury.
2025년 1월 28일 이벤트

​Antibody Drug Conjugates Keep Growing: What You Need to Know

Since 2018, there has been an exponential growth of over US$60 billion of licensing deals involving Antibody Drug Conjugates (ADCs), with 2023 having at least 18 deals. ADCs worldwide are projected to reach US$20-30 billion per year in the near future.
장갑을 낀 손이 파란색과 보라색 박테리아 배양액이 담긴 배양 접시를 들고 있으며, 배경에는 지적 재산권으로 보호되는 혁신적인 발견처럼 흐릿한 원형 현미경 이미지가 있습니다.
December 11, 2024 Health Care Law Today

항체 약물 접합체는 계속 성장하고 있습니다: 알아야 할 사항

지난 몇 년 동안 헬스케어 및 생명과학과 혁신 기술 부문은 기업과 사모펀드 모두 투자처를 재평가하면서 거래 건수가 감소했습니다.
Abstract digital artwork featuring colorful, glowing dots and lines creates a swirling, wave-like pattern on a dark blue background—an inspired visual echoing the dynamic energy often found in top lawyers in Chicago.
August 13, 2024 Health Care Law Today

Cancer Drugs: Antibody-Drug Conjugate Litigation

The first step to making a product available to the clinical population is often obtaining patent protection, resulting in litigation around ADCs.
피펫이 컬러 막대가 있는 디지털 DNA 시퀀싱 패턴 위에 놓인 페트리 접시에 액체를 분사하여 생명공학 혁신과 지적재산권법의 교차점을 강조합니다.
2024년 4월 29일 의료법의 오늘

2024년 헬스케어 및 생명 과학 주요 트렌드

Foley & Lardner의 2024 헬스케어 및 생명과학 주요 트렌드 간행물에서는 빠르게 변화하는 개발 동향을 분석하여 비즈니스에 도움이 되는 정보를 제공합니다.